- Trodelvy misses in lung cancer, but Gilead and Merck have an HIV successGilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…Endpoints · 1mo ago↗ source
- Endpoints Women in Biopharma: Nominate for 2026Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…Endpoints · 1mo ago↗ source
- Pharma and biotech salaries: Top-paying companies of 2025The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…